Loading...
Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE".
Schöffski, P Wozniak, A Casali, P Rutkowski, P Blay, J Lindner, L Strauss, S Anthoney, A Duffaud, F Richter, S
Schöffski, P
Wozniak, A
Casali, P
Rutkowski, P
Blay, J
Lindner, L
Strauss, S
Anthoney, A
Duffaud, F
Richter, S
Citations
Altmetric:
Abstract
Clear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA.
Description
Date
2017-09-18
Publisher
Collections
Files
Loading...
Main article
Adobe PDF, 52.98 KB
Keywords
Type
Article
Citation
Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". 2017, Ann Oncol